A systematic comparison of 18F-C-SNAT to established radiotracer imaging agents for the detection of tumor response to treatment

Clinical Cancer Research

Volumn 21, Issue 17, 2015, Pages 3896-3905

  Witney, Timothy H ^a   Hoehne, Aileen ^a   Reeves, Robert E ^a   Ilovich, Ohad ^a   Namavari, Mohammad ^a   Shen, Bin ^a   Chin, Frederick T ^a   Rao, Jianghong ^a   Gambhir, Sanjiv S ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANNEXIN V TC 99M; C SNAT F 18; CARBOPLATIN; CASPASE 3; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; ML 10 F 18; RADIOPHARMACEUTICAL AGENT; TRACER; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BENZOTHIAZOLE DERIVATIVE; C-SNAT COMPOUND; OLIGOPEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER PROGNOSIS; CANCER THERAPY; CELL DEATH; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; DRUG DISTRIBUTION; DRUG STRUCTURE; DRUG UPTAKE; EX VIVO STUDY; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; LUNG CANCER CELL LINE; LYMPHOMA CELL; MOUSE; NON SMALL CELL LUNG CANCER; NONHUMAN; PATIENT CARE; PET-CT SCANNER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION; RADIOACTIVITY; TISSUE SECTION; TREATMENT RESPONSE; TUMOR CELL CULTURE; TUNEL ASSAY; ANIMAL; BIOAVAILABILITY; DISEASE MODEL; DRUG EFFECTS; METABOLISM; NEOPLASMS; PROCEDURES; TREATMENT OUTCOME; TUMOR CELL LINE; TUMOR VOLUME; X-RAY COMPUTED TOMOGRAPHY;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZOTHIAZOLES; BIOLOGICAL AVAILABILITY; CELL DEATH; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MICE; NEOPLASMS; OLIGOPEPTIDES; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84942931457     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-3176     Document Type: Article

References (43)

1. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-47.
2. Kreuzaler P, Watson CJ. Killing a cancer: what are the alternatives? Nat Rev Cancer 2012; 12: 411-24.
3. Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature 2001; 411: 342-8.
4. Sellers WR, Fisher DE. Apoptosis and cancer drug targeting. J Clin Invest 1999; 104: 1655-61.
5. Neves AA, Brindle KM. Imaging cell death. J Nucl Med 2014; 55: 1-4.
6. Nguyen QD, Smith G, Glaser M, Perumal M, Arstad E, Aboagye EO. Positron emission tomography imaging of drug-induced tumor apoptosis with a caspase-3/7 specific [18F]-labeled isatin sulfonamide. Proc Natl Acad Sci U S A 2009; 106: 16375-80.
7. Shen B, Jeon J, Palner M, Ye D, Shuhendler A, Chin FT, et al. Positron emission tomography imaging of drug-induced tumor apoptosis with a caspase-triggered nanoaggregation probe. Angew Chem Int Ed Engl 2013; 52: 10511-4.
8. Blankenberg FG, Katsikis PD, Tait JF, Davis RE, Naumovski L, Ohtsuki K, et al. Imaging of apoptosis (programmed cell death) with 99mTc annexin V. J Nucl Med 1999; 40: 184-91.
9. Zhao M, Li Z, Bugenhagen S. 99mTc-labeled duramycin as a novel phos-phatidylethanolamine-binding molecular probe. J Nucl Med 2008; 49: 1345-52.
10. Segawa K, Kurata S, Yanagihashi Y, Brummelkamp TR, Matsuda F, Nagata S. Caspase-mediated cleavage of phospholipid flippase for apoptotic phos-phatidylserine exposure. Science 2014; 344: 1164-8.
11. Day SE, Kettunen MI, Gallagher FA, Hu DE, Lerche M, Wolber J, et al. Detecting tumor response to treatment using hyperpolarized 13C magnetic resonance imaging and spectroscopy. Nat Med 2007; 13: 1382-7.
12. Witney TH, Kettunen MI, Day SE, Hu DE, Neves AA, Gallagher FA, et al. A comparison between radiolabeled fluorodeoxyglucose uptake and hyperpolarized C-13-labeled pyruvate utilization as methods for detecting tumor response to treatment. Neoplasia 2009; 11: 574-U88.
13. Gallagher FA, Kettunen MI, Hu DE, Jensen PR, Zandt RI, Karlsson M, et al. Production of hyperpolarized [1,4-13C2]malate from [1,4-13C2]fumarate is a marker of cell necrosis and treatment response in tumors. Proc Natl Acad Sci U S A 2009; 106: 19801-6.
14. Witney TH, Kettunen MI, Hu DE, Gallagher FA, Bohndiek SE, Napolitano R, et al. Detecting treatment response in a model of human breast adenocarcinoma using hyperpolarised [1-C-13]pyruvate and [1,4-C-13 (2)]fumarate. Br J Cancer 2010; 103: 1400-6.
15. Sinkus R, Van Beers BE, Vilgrain V, DeSouza N, Waterton JC. Apparent diffusion coefficient from magnetic resonance imaging as a biomarker in oncology drug development. Eur J Cancer 2012; 48: 425-31.
16. Avril N, Sassen S, Schmalfeldt B, Naehrig J, Rutke S, Weber WA, et al. Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer. J Clin Oncol 2005; 23: 7445-53.
17. Schelling M, Avril N, Nahrig J, Kuhn W, Romer W, Sattler D, et al. Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol 2000; 18: 1689-95.
18. Spaepen K, Stroobants S, Dupont P, Van Steenweghen S, Thomas J, Vandenberghe P, et al. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods? J Clin Oncol 2001; 19: 414-9.
19. Weber WA, Petersen V, Schmidt B, Tyndale-Hines L, Link T, Peschel C, et al. Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol 2003; 21: 2651-7.
20. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 2009; 50: 122S-50S.
21. Grimberg H, Levin G, Shirvan A, Cohen A, Yogev-Falach M, Reshef A, et al. Monitoring of tumor response to chemotherapy in vivo by a novel small-molecule detector of apoptosis. Apoptosis 2009; 14: 257-67.
22. Reshef A, Shirvan A, Waterhouse RN, Grimberg H, Levin G, Cohen A, et al. Molecular imaging of neurovascular cell death in experimental cerebral stroke by PET. J Nucl Med 2008; 49: 1520-8.
23. Hoglund J, Shirvan A, Antoni G, Gustavsson SA, Langstrom B, Ringheim A, et al. 18F-ML-10, a PET tracer for apoptosis: first human study. J Nucl Med 2011; 52: 720-5.
24. Hoebers FJ, Kartachova M, de Bois J, van den Brekel MW, van Tinteren H, van Herk M, et al. 99mTc Hynic-rh-Annexin V scintigraphy for in vivo imaging of apoptosis in patients with head and neck cancer treated with chemoradiotherapy. Eur J Nucl Med Mol Imaging 2008; 35: 509-18.
25. Belhocine T, Steinmetz N, Hustinx R, Bartsch P, Jerusalem G, Seidel L, et al. Increased uptake of the apoptosis-imaging agent (99m)Tc recombinant human Annexin V in human tumors after one course of chemotherapy as a predictor of tumor response and patient prognosis. Clin Cancer Res 2002; 8: 2766-74.
26. Reshef A, Shirvan A, Akselrod-Ballin A, Wall A, Ziv I. Small-molecule biomarkers for clinical PET imaging of apoptosis. J Nucl Med 2010; 51: 837-40.
27. Witney TH, Fortt RR, Aboagye EO. Preclinical assessment of carboplatin treatment efficacy in lung cancer by 18F-ICMT-11-positron emission tomography. PLoS ONE 2014; 9: e91694.
28. Larkin TJ, Canuto HC, Kettunen MI, Booth TC, Hu DE, Krishnan AS, et al. Analysis of image heterogeneity using 2D Minkowski functionals detects tumor responses to treatment. Magn Reson Med 2014; 71: 402-10.
29. Ardizzoni A, Boni L, Tiseo M, Fossella FV, Schiller JH, Paesmans M, et al. Cisplatin-versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst 2007; 99: 847-57.
30. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235-42.
31. Cohen A, Shirvan A, Levin G, Grimberg H, Reshef A, Ziv I. From the Gla domain to a novel small-molecule detector of apoptosis. Cell Res 2009; 19: 625-37.
32. Ben-Haim S, Ell P. 18F-FDG PET and PET/CT in the evaluation of cancer treatment response. J Nucl Med 2009; 50: 88-99.
33. Strauss LG Fluorine-18 deoxyglucose and false-positive results: a major problem in the diagnostics of oncological patients. Eur J Nucl Med 1996; 23: 1409-15.
34. Yamane T, Daimaru O, Ito S, Yoshiya K, Nagata T, Ito S, et al. Decreased 18F-FDG uptake 1 day after initiation of chemotherapy for malignant lymphomas. J Nucl Med 2004; 45: 1838-42.
35. Spaepen K, Stroobants S, Dupont P, Bormans G, Balzarini J, Verhoef G, et al. [(18)F]FDG PET monitoring of tumour response to chemotherapy: does [(18)F]FDG uptake correlate with the viable tumour cell fraction? Eur J Nucl Med Mol Imaging 2003; 30: 682-8.
36. Alam IS, Neves AA, Witney TH, Boren J, Brindle KM. Comparison of the C2A domain of synaptotagmin-Iand Annexin-Vasprobes for detecting cell death. Bioconjug Chem 2010; 21: 884-91.
37. Blankenberg FG, Vanderheyden JL, Strauss HW, Tait JF. Radiolabeling of HYNIC-annexin V with technetium-99m for in vivo imaging of apoptosis. Nat Protoc 2006; 1: 108-10.
38. Grafstrom J, Stone-Elander S. Comparison of methods for evaluating radiolabelled Annexin A5 uptake in pre-clinical PET oncological studies. Nucl Med Biol 2014; 41: 793-800.
39. Hu S, Kiesewetter DO, Zhu L, Guo N, Gao H, Liu G, et al. Longitudinal PET imaging of doxorubicin-induced cell death with 18F-Annexin V. Mol Imaging Biol 2012; 14: 762-70.
40. Ye D, Shuhendler AJ, Cui L, Tong L, Tee SS, Tikhomirov G, et al. Bioorthogonal cyclization-mediated in situ self-assembly of small-molecule probes for imaging caspase activity in vivo. Nat Chem 2014; 6: 519-26.
41. Nguyen QD, Lavdas I, Gubbins J, Smith G, Fortt R, Carroll LS, et al. Temporal and spatial evolution of therapy-induced tumor apoptosis detected by caspase-3-selective molecular imaging. Clin Cancer Res 2013; 19: 3914-24.
42. Challapalli A, Kenny LM, Hallett WA, Kozlowski K, Tomasi G, Gudi M, et al. 18F-ICMT-11, a caspase-3-specific PET tracer for apoptosis: biodistribution and radiation dosimetry. J Nucl Med 2013; 54: 1551-6.
43. Glaser M, Goggi J, Smith G, Morrison M, Luthra SK, Robins E, et al. Improved radiosynthesis of the apoptosis marker 18F-ICMT11 including biological evaluation. Bioorg Med Chem Lett 2011; 21: 6945-9.